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S U M M A R Y
Objectives: Since the initial discovery of Plasmodium knowlesi in Malaysia, cases have been reported from
several neighbouring countries. Tourism has also resulted in an increasing number of cases diagnosed in
Europe, America, and Oceania. In this review we focus on the risk of the travel-associated acquisition of P.
knowlesi malaria.
Methods: A search of the literature in PubMed was carried out to identify articles and literature on the
distribution of P. knowlesi infections in Southeast Asia and details of its acquisition and importation by
travellers to other continents. The cut-off date for the search was December 1, 2013. Search words used
were: ‘‘Plasmodium knowlesi’’, ‘‘Plasmodium knowlesi infections’’, ‘‘Plasmodium knowlesi travellers’’,
‘‘Plasmodium knowlesi prevalence’’, ‘‘Plasmodium knowlesi host’’, ‘‘Plasmodium knowlesi vector’’
‘‘Plasmodium knowlesi RDT’’, and ‘‘Plasmodium knowlesi Malaysia’’.
Traveller numbers to Malaysia were obtained from the Tourism Malaysia website.
Results: A total of 103 articles were found. Using a selection of these and others identiﬁed from the
reference lists of the papers, we based our review on a total of 66 articles.
Results: P. knowlesi malaria appears to be the most common malaria species in Malaysian Borneo and is
also widely distributed on the Malaysian mainland. Furthermore, locally transmitted cases of P. knowlesi
malaria have been reported in Thailand, the Philippines, Vietnam, Singapore, Myanmar, Indonesian
Borneo, and Cambodia. Two cases have been reported from non-endemic countries in Asia (Japan and
Taiwan) in people with a history of travel to Malaysia and the Philippines. Twelve cases were imported to
their home countries by travellers from other continents: two from the USA, two from the Netherlands,
two from Germany, and one each from Spain, France, Sweden, Finland, Australia, and New Zealand. In
most cases, the infection was associated with a trip to or near forested areas. The symptoms were fever
(n = 12), headache (n = 6), chills (n = 6), nausea (n = 4), myalgia (n = 3), back pain (n = 3), abdominal
problems (n = 1), anorexia (n = 2), fatigue (n = 2), malaise (n = 1), arthralgia (n = 1), sore throat (n = 1)
vomiting (n = 2), and jaundice (n = 1). All patients were treated successfully with currently available
antimalaria treatments. The identiﬁcation of the pathogen by microscopy can be problematic due to the
morphological similarity of P. knowlesi to Plasmodium malariae.
Conclusion: P. knowlesi appears to be a threat not only to the local population in Malaysia, but also to the
estimated 25 million annual tourists and occupational travellers to Malaysia, especially those who visit
rural, forested areas of the country. The P. knowlesi risk is not limited to Malaysia, and travellers from
Southeast Asia presenting with possible malaria should be considered for a diagnostic work-up that
includes P. knowlesi.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
Contents lists available at ScienceDirect
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Plasmodium knowlesi was probably discovered by Franchini in
1927 in its natural simian host, Macaca fascicularis, and was
described for the ﬁrst time in morphological detail in 1932 by
Knowles and Das Gupta, who also managed to show transmission* Corresponding author.
E-mail address: mueller.mattia@gmail.com (M. Mu¨ller).
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http://dx.doi.org/10.1016/j.ijid.2013.12.016from monkeys to human volunteers under laboratory conditions.1–3
Up to 1965, P. knowlesi was known only as a simian parasite. This
changed when it was found in the blood of a US Army Map Service
surveyor who had spent 4 weeks in Malaysia.4 With a focus on
naturally acquired P. knowlesi infections in human beings, Singh
et al. showed that, in Kapit Division (Sarawak, Malaysia), 58% of 208
microscopically diagnosed malaria patients were actually positive
for P. knowlesi by PCR. These ﬁndings led to the recognition of P.
knowlesi as the ﬁfth human malaria parasite.5 Since then different
PCR studies have shown that P. knowlesi is a common malaria
Plasmodium species in Malaysian Borneo.6–9 In 2008, 27.2% of 980
malaria patients from 12 hospitals of Sarawak showed the simianociety for Infectious Diseases. Open access under CC BY-NC-ND license.
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state Sabah, some 78% of 220 malaria-positive patients were
considered to be afﬂicted with P. knowlesi mono-infections and 9%
with mixed infections,8 while in Sandakan Division, 23.6% were
reported to be positive for this Plasmodium species.10 Another study
in which nested PCR was used in Sabah, showed 63 P. knowlesi single
infections and two mixed infections out of 107 Plasmodium spp-
positive samples.9
The analysis of archival blood ﬁlms suggests that, already in
1996, P. knowlesi accounted for a large part of microscopically
diagnosed Plasmodium malariae infections in Sarawak,11 and
according to the more recent investigations, it appears to have
increased in recent decades.12 Also, this Plasmodium species has
been detected in different states of Peninsular Malaysia.13,14
However the ﬁfth malaria parasite is not geographically limited to
Malaysian Borneo and the Malaysian mainland. In Thailand, the
existence of P. knowlesi has been reported at different locations
throughout the country.15–17 In Vietnam, three cases have been
reported from Ninth Thuan Province18 and 32 PCR-positive blood
samples from Nga Hai and Da Tai (Khanh Hoa Province).19 Six more
cases have been reported in the forested part of Singapore,20,21 32
from southern Myanmar,22 six from the Philippine island of
Palawan,23 and two cases have been described in Cambodia near
the border with Thailand.24
P. knowlesi is transmitted by mosquitoes of the Anopheles
leucosphyrus group.13,25,26 The natural hosts include long-tailed
macaques (M. fascicularis), pig-tailed macaques (Macaca nemes-
trina), and banded leaf monkeys (Presbytis melalophos).27 The
prevalence of infection in long- and pig-tailed macaques in Kapit
Division (Sarawak, Malaysia) is up to 78%.28
For intercontinental travellers, the signiﬁcance of P. knowlesi
infections became clear when, in 2006, a Swedish traveller
presented to a Stockholm hospital with a P. knowlesi-positive
blood picture after a 2-week holiday in Sarawak, Malaysian
Borneo.29 Since then, there have been several reports of imported
P. knowlesi cases all over the world.30–39
This review presents an overview of available knowledge on
Plasmodium knowlesi with a focus on the risk of travel-associated
acquisition of this malaria species. (Figs. 1 and 2)
2. Methods
The data were compiled from searches of PubMed using the
following search terms, alone or in combination: ‘‘Plasmodium
knowlesi’’, ‘‘Plasmodium knowlesi infections’’, ‘‘Plasmodium knowlesi
travellers’’, ‘‘Plasmodium knowlesi prevalence’’, ‘‘Plasmodium know-
lesi host’’, ‘‘Plasmodium knowlesi vector’’, ‘‘Plasmodium knowlesi
RDT’’, and ‘‘Plasmodium knowlesi Malaysia’’. References of the
selected articles were also searched to complete the documenta-
tion. Traveller numbers to Malaysia were sourced from the website
of Tourism Malaysia. The cut-off date for the collation of
information was December 1, 2013.
3. Results and discussion
We used a selection of the 103 papers resulting from our
PubMed screening, with the addition of further papers identiﬁed
from the references lists. Furthermore we used statistics on
tourism in Malaysia obtained from the ofﬁcial website of Tourism
Malaysia.
3.1. P. knowlesi in international travellers (Table 1)
The ﬁrst reported case of a naturally transmitted P. knowlesi
infection concerned a surveyor from the US Army in 1965.4 This
early report suggested that the parasite could also be a threat tointernational occupational and holiday travellers. Since then,
further cases of P. knowlesi infection probably acquired during a
holiday or work-related trip have been reported from non-endemic
countries in Asia (n = 2),40,41 as well as from other continents
(n = 11).29–38 In Europe, the two ﬁrst conﬁrmed imported P.
knowlesi cases occurred in 2006/2007. The ﬁrst was a Swedish
traveller who had returned from a trekking tour of the jungle area
of the Bario Highlands in Malaysian Borneo.29 The second was a
Finnish man who had travelled in Peninsular Malaysia during
March 2007.30 Since then, six more cases have been reported in
Europe, in tourists from Spain,32 France,36 the Netherlands,37 and
Germany,38,39 and from a Malay (Sarawak) immigrant to the
Netherlands.33 In the southern hemisphere, two imported cases
are known, one in Australia34 and one in New Zealand.35 One
patient had worked several times in Kalimantan, Indonesian
Borneo34 and the other in Sabah and Sarawak (Malaysian
Borneo).35 A further P. knowlesi infection, besides the early 1965
case, was found in the USA, in a female patient who had visited
relatives on Palawan Island in the Philippines.31 From these 12
reported cases in intercontinental travellers, only three cases
involved female patients.31,37,39 The period of travel in the risk area
varied from 1 week to several months.4,29–39 In nearly all cases, a
history of travel to a forested area with overnight stays was
included.4,29,30,32–35,37,38 No stay in a forest was reported for only
two cases, a female patient visiting relatives on Palawan Island in
the Philippines31 and a French tourist spending his holidays on a
tourist beach on the Island of Ko Pyang in Thailand36. In both cases,
however, the travellers were on the edge of a forested area, but
never entered it.31,36
3.2. Clinical and laboratory parameters
In a clinical study, Daneshvar et al. reported fever and chills to be
the common symptoms, identiﬁed in 100% of the investigated
cases.6 Furthermore headache, rigors, malaise, anorexia, myalgia,
arthralgia, cough, and abdominal pain were frequently observed.
Tachycardia and tachypnea were noted as common clinical signs.6,42
In the 12 intercontinental traveller cases, the ﬁrst common
symptom was fever. Other symptoms were headache (n = 6), chills
(n = 6), nausea (n = 4), myalgia (n = 3), back pain (n = 3), abdominal
problems (n = 1), anorexia (n = 2), fatigue (n = 2), malaise (n = 1),
arthralgia (n = 1), sore throat (n = 2) vomiting (n = 1), and jaundice
(n = 1).4,29–39 In one case, symptoms of hypoglycaemia with slight
hearing and visual loss were reported during treatment with
quinine and doxycycline.30 In most cases, the ﬁrst clinical
symptoms were present 2–13 days after leaving the country of
probable acquisition. Only in the case of a 32-year-old Dutch
woman were the symptoms already present in the country
travelled to.37 Clinical examination showed an increased temper-
ature (range 38.8–40.2 8C) in all 12 traveller patients.4,29–38 In only
three of 10 cases in whom it was measured, was anaemia found to
be present.29,33,38 Leukocyte counts were lowered in ﬁve
cases.29,30,32,34,37 Thrombocytopenia was present in all patients
in whom platelet levels were determined.29–39 Six publications
reported an increase in the liver enzyme alanine aminotransferase
and ﬁve an increased aspartate aminotransferase.29,32,33,36,37 Renal
failure was diagnosed with an increase in creatinine up to 3.45 mg/
dl in a German woman.39
According to the adapted World Health Organization (WHO)
criteria for severe malaria infection by Barber et al., two of the
traveller cases could be considered to have had severe infections. In
one case this was due to high parasite and bilirubin levels,33 and in
another to rising creatinine levels during hospitalization.39,42
Concerning the prognosis, Willmann et al. postulated that patients
with P. knowlesi infections and a parasite count 35 000/ml or 1%,
or a platelet count 45  109/l, should be considered as at risk of
Figure 1. Distribution of reported Plasmodium knowlesi infections in Southeast Asia.
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correlation only with parasitemia (20 000/ml) as a signiﬁcant
marker of severity.42 Therefore, according to Willmann et al., two
more patients could be considered to have been at potential risk of
further complications because of their low platelet levels or high
parasitemia,29,31,33,43 and a further case also by the criteria of
Barber et al.4,42 (Table 1 and Table 2)
3.3. Diagnosis of P. knowlesi malaria
The ‘gold standard’ for the diagnosis of most Plasmodium
species is microscopic examination because it is rapid andFigure 2. Plasmodium knowlesi cases exportedinexpensive and accurate in expert hands. The disadvantage in
its application for the diagnosis of P. knowlesi is the large number of
false-negatives or misdiagnosed cases due to the morphological
similarity with P. falciparum in the early trophozoite stage and with
P. malariae in the late and mature trophozoites, gametocytes, and
schizonts.5,44
The ﬁrst nested PCR applied to P. knowlesi diagnosis was
described by Singh et al.5 However, in its application, the primer
pair resulted in a small number of false-positive results due to
cross-reactivity with Plasmodium vivax.45 Since then, additional
nested PCR primers and real-time PCR procedures with a higher
sensitivity have been developed.45–48 Although PCR is one of the from Southeast Asia to other continents.
Table 1
Intercontinental travellers diagnosed with Plasmodium knowlesi
Ref. Year of
acquisition
Country of
presentation
Presumed area of
acquisition
Journey to potential risky
areas (forest, jungle)
Interval between
leaving the country
of acquisition and
presentation with
symptoms
Symptoms Treatment Prophylaxis
Chin et al.4 1965 USA Peninsular Malaysia NA NA Sore throat, chills, fever,
sweating, anorexia,
fatigue, nausea
Chloroquine,
primaquine
NA
Bronner et al.29 2006 Sweden Sarawak, Malaysia, Borneo Jungle of the Bario
Highlands
11 days Fever (40 8C), sweating,
headache, fatigue
Meﬂoquine No
Kantele et al.30 2007 Finland Kuala Lumpur, Malaysia;
Ipoh, Malaysia; Langkawi,
Malaysia
Surrounding areas,
jungle
3 days Fever (38.8 8C), abdominal
problems, attack of
hypoglycaemia with
transient mild hearing
and visual loss
Quinine
dihydrochloride,
doxycycline
Later: primaquine
No
CDC31 2008 USA Island of Palawan, Philippines No (edge of forest area) NA Headache, fever, chills Atovaquone/
proguanil,
primaquine
No
Ta et al.32 2008/2009 Spain Bangkok, Thailand
Banda Ace + Pulau Weh, Indonesia
Kuala Lumpur, Malaysia
Hanoi, Vietnam
Rural areas NA Fever (40.0 8C), arthralgia,
myalgia, low back pain,
chills, malaise
Chloroquine Meﬂoquine
(changed because
of adverse drug
reaction)
Atovaquone/
proguanil (took 80%
of prescription)
van Hellmond et al.33 2009 Netherlands Kapit, Sarawak, Malaysia Jungle 2 days Fever (40.0 8C), myalgia,
headache, low back pain
Chloroquine -
Figtree et al.34 2010a Australia Kalimanta, Indonesia Forest 13 days Fever, mild headaches Atovaquone/
proguanil
-
Hoosen and Shaw35 2010 New Zealand Sabah, Malaysia; Sarawak,
Malaysia
Forest 7–9 days Fever (39.1 8C), myalgia Atovaquone/
proguanil
Later: artemether/
lumefantrine
-
Berry et al.36 2010 France Ranong, Thailand; Island of
Ko Payam, Thailand
No (edge of forest area) 9 days Fever, shivering, nausea,
anorexia
Chloroquine -
Link et al.37 2011 Netherlands Borneo, Malaysia Jungle 1 day before leaving
country of probable
acquisition
Fever (40.2 8C), chills,
nausea, vomiting, severe,
headache, backache
Atovaquone/
proguanil
No
Ehrhardt et al.38 2013a Germany Ranong, Thailand Forest 9 days Fever (40.0 8C), chills,
severe, headaches
Atovaquone/
proguanil
No
Orth et al.39 2013a Germany Khoa Sok, Thailand National Park 10 days Fever, nausea, vomiting Artesunate,
artemether/
lumefantrine
-
NA, information not available.
a The year of infection was unclear, so the year of publication has been used.
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time, money, and well-trained personnel, and for these reasons it is
not ideal in most settings.49
Currently available rapid diagnostic tests (RDTs) based on
monoclonal antibodies (MAbs) capturing pan-Plasmodium lactate
dehydrogenase (pan-pLDH) and genus-speciﬁc aldolase (pan-
aldolase), only have a sensitivity of 74% and 23%, respectively,
and do not distinguish between the non-falciparum species.50 In
2008, the team of McCutchan analysed the reactivity of known
Plasmodium LDH-speciﬁc MAbs. In this experiment, McCutchan
et al. were able to distinguish P. knowlesi from P. malariae
infections. However the detection of P. knowlesi infections is
confounded by the difﬁculty in distinguishing P. knowlesi from
mixed falciparum–vivax infections.51 In 2011, Piper et al. devel-
oped a model for a new test format based on three test strips, with
which the four human Plasmodium species and P. knowlesi could be
differentiated.52
Iseki et al. in Japan (2010) and Lau et al. in Malaysia (2011)
created P. knowlesi-speciﬁc primers against b-tubulin53 and apical
membrane antigen-1,49 which can be used in a loop-mediated
isothermal ampliﬁcation (LAMP). The advantages compared to PCR
are the velocity (109 copies of a targeted gene in 1 h) and the
required isotherm conditions, which allow the use of simpler and
cheaper techniques such as an incubator.53 The exact niche for this
diagnostic approach has yet to be established.
3.4. Treatment and chemoprophylaxis
The most frequently reported drug treatment for P. knowlesi
infections in the papers reviewed was a combination of chloro-
quine and primaquine.4–6,8,23,54 Due to the fact that no hypnozoites
have ever been described in P. knowlesi infections, primaquine is
probably not required as a treatment, except in cases of mixed
infection with P. vivax. In one study, the time to clear 90% of the
parasitemia present at admission was deﬁned as 10.3 h with a
fever remission time of 26.5 h in adults. The dosage used was
25 mg/kg chloroquine over 2 days and additionally 15 mg
primaquine.54 Children with the same drug combination showed
a much slower mean parasite clearance of 2 days. A signiﬁcant
correlation has been shown between the parasite concentration in
the blood and the time to parasite clearance.8 A recent study
revealed the efﬁciency of artemisinin-based combination therapy
(ACT) with artemether–lumefantrine and artesunate–meﬂoquine
for non-severe P. knowlesi infections, or intravenous artesunate
for severe infections.42 A faster parasite clearance was reported
with artemether–lumefantrine and artesunate compared toTable 2
Laboratory parameters of intercontinental travellers with Plasmodium knowlesi infectio
Ref. Case Temp., 8C Leukocytesa T
Chin et al.4 USA, 1965 40.4 NA N
Bronner et al.29 Sweden, 2006 40.0 2.2  109/l # 3
Kantele et al.30 Finland, 2007 38.8 2.6  109/l # 1
CDC31 USA,2008 NA NA T
Ta et al.32 Spain, 2008/2009 40.0 3.82  109/l # 8
van Hellmond et al.33 Netherlands, 2009 40.0 5.8  109/l 2
Figtree et al.34 Australia, 2010b 38.9 3.7  109/l # 1
Hoosen and Shaw35 New Zealand, 2010 39.1 4.3  109/l 7
Berry et al.36 France, 2010 NA Normal 7
Link et al.37 Netherlands, 2011 40.2 3.5  109/l # 7
Ehrhardt et al.38 Germany, 2013b 40.0 4.1  109/l 1
Orth et al.39 Germany, 2013 NA 7.36  109/l 2
ALT, alanine aminotransferase; AST, aspartate aminotransferase; NA, information not a
a # Value lower than locally used reference value; " value higher than locally used r
b The year of infection was unclear, so the year of publication has been used.chloroquine and quinine.42 Even if at the present time, large
studies on the other established malaria treatments are missing,
several single reports have underlined the efﬁciency of the
different currently available drugs. The documented successful
treatment with different combinations of chloroquine, prima-
quine, artemisinin combinations, sulfadoxine, pyrimethamine, and
quinine are shown in Table 5. Meﬂoquine was described three
times as an effective therapy.24,29,40 In another case report
involving a re-infected Malaysian businessman during an expedi-
tion in Tanjung Malim, Perak, Malaysia, the parasitemia continued
to increase despite a total administration of 1.5 g of meﬂoquine.
The man, who presented symptoms of chills, rigors, epigastric pain,
nausea, and vomiting after an expedition with overnight camping,
was started on initial therapy of 750 mg meﬂoquine with two
successive doses of 500 mg after 6 h and 250 mg after 12 h. Despite
treatment, the parasitemia increased from 1.0% to 2.5%. Medication
was changed to quinine, doxycycline, and the combination
artemether and lumefantrine. Parasitemia eventually cleared on
day 5 of admission to the hospital.55 There may be potential
resistance of some P. knowlesi strains against meﬂoquine.
Experiments with infected rhesus monkeys showed a suppressive
activity of meﬂoquine but without complete cure against P.
knowlesi infections.56,57 Recent studies have indicated an innate
immunity to meﬂoquine in vitro, as well in ex vivo experiments.58
Data regarding chemoprophylaxis for prevention are missing,
but the fact that none of the infected cases reported so far had
received adequate prophylaxis could indicate an effect of known
preventive anti-malaria drugs against P. knowlesi as well. Only one
case, a Spanish traveller, had used meﬂoquine and later
atovaquone/proguanil chemoprophylaxis; this case developed a
mild P. knowlesi infection but later recovered without further
treatment.32 (Table 3, Table 4 and Table 5).
3.5. Risk and advice for travellers
In 2012, 25 032 708 tourist arrivals were registered in
Malaysia. Most of them were from Asian countries, especially
from Singapore, Thailand, Indonesia, Brunei, and China. In the
same year, Tourism Malaysia reported an increase to 1 002 067
European travellers (from the UK, France, Germany, Netherlands,
Italy, Sweden, Switzerland, Denmark, Spain, Ireland, Norway,
Belgium, Austria, and Poland), 327 065 from the USA and Canada,
and 573 674 from New Zealand and Australia.59 The risk of
transmission therefore appears low for intercontinental travel-
lers considering that only 14 cases have been reported beyond
endemic areas.ns
hrombocytesa ALTa ASTa Parasitemia
A NA NA 20 850/ml
4  109/l # 1.68 mcat/l " NA NA
43  109/l # NA NA <1%
hrombocytopenia not speciﬁed NA NA 2.9%
6  109/l # 93U/l " 43 U/l " 0.003%
250/ml
2  109/l # 199 U/l " 128 U/l " 2%
84 000/ml
06  109/l # NA NA 185/ml
1  109/l # NA NA NA
3  109/l # 75 U/l " 58 U/l " 0.8%
2  109/l # 80 U/l " 76 IU/l " 0.0005%
97  109/l NA NA 0.01%
473/ml
7  109/l # 277 U/l " 237 U/l " 0.2%
vailable.
eference value.
Table 3
Diagnostic methods used to investigate Plasmodium knowlesi infections in intercontinental travellers, and the results
Ref. Case Microscopy RDTs Nested PCR Real-time PCR Other or not nearer
speciﬁed PCRs
Chin et al.4 USA, 1965 Positive for P. falciparum
(1st examination)
Positive for P. malariae
(2nd examination)
Later positive for P.
knowlesia
- - - -
Bronner et al.29 Sweden, 2006 Suspicion for P. malariae Negative
(BinaxNOWb)
Positive for P. knowlesi
(nested PCR and
sequencing of the SSU
rRNA)
- Negative (PCR
speciﬁc for P.
falciparum, P. vivax,
P. ovale, P. malariae)
Kantele et al.30 Finland, 2007 Positive for P. falciparum
(1st examination)
Positive for co-infection of
P. falciparum and P.
malariae (2nd
examination)
- Negative (nested PCR with
rOva1 and rPLU2 primers)
Positive for P. knowlesi
(nested PCR and
sequencing with rPLU6
and rPLU2 primers)
- -
CDC31 USA, 2008 Positive for unspeciﬁc
malaria
- - - Negative for: P.
malariae, P.
falciparum, P. ovale,
P. vivax
(conventional PCR
targeting the SSU
rRNA)
Positive for P.
knowlesi
(conventional PCR
with primer
speciﬁc for the SSU
rDNA of
Plasmodium genus
and sequencing)
Ta et al.32 Spain, 2008/2009 Positive for unspeciﬁc
malaria
Negative for HRP2
Negative for pan-
malarial aldolase
(BinaxNOWb)
- Positive for P.
knowlesi (real-time
PCR with
sequencing of the
SSU rRNA)
Positive for P.
knowlesi (multiplex
real-time PCR
speciﬁc for
Plasmodium genus,
P. falciparum, P.
vivax and
sequencing)
van Hellmond
et al.33
Netherlands, 2009 Positive for unspeciﬁc
malaria
Negative for HRP2
Positive for pan-
malarial aldolase
(BinaxNOWb)
Negative for P. malariae, P.
falciparum, P. ovale, P.
vivax (nested PCR)
Positive for P. knowlesi
(nested PCR with rPLU1
and rPLU5 primers,
species-speciﬁc primers
targeting the SSU rRNA
and sequencing)
Negative for P.
malariae, P.
falciparum, P. ovale,
P. vivax (real-time
PCR)
-
Figtree et al.34 Australia, 2010c Positive for P. malariae or
P. falciparum
Negative for HRP2 Positive for P. knowlesi
(nested PCR with P.
knowlesi-speciﬁc primers
(Pmk8 Pmkr9) and
sequencing of SSU rRNA)
- Negative for P.
malariae, P.
falciparum, P. ovale,
P. vivax (multiplex
PCR)
Hoosen and
Shaw35
New Zealand, 2010 Negative (1st and 2nd
examination)
Suspected P. malariae (3rd
examination)
Negative for P.
falciparum and
other Plasmodium
antigen
- - Positive for P.
knowlesi (PCR and
sequencing)
Berry et al.36 France, 2010 Positive for mixed P.
malariae and P. falciparum
infection (1st and 2nd
examinations)
Positive for P. vivax-
speciﬁc LDH
Positive for pan-
Plasmodium LDH
Negative for HRP2
(Core Malaria Pan/
Pv/Pf testd)
Positive for pan-
Plasmodium
aldolase
Negative for HRP2
(BinaxNOWe)
Positive for P. vivax-
speciﬁc LDH
Positive for pan-
Plasmodium LDH
Negative for HRP2
(Palutop testf)
- Positive for malaria
Negative for P.
falciparum
(multiplex real-
time PCR)
Positive for P. vivax
Negative for: P.
ovale, P. malariae
(real-time PCR
speciﬁc for P.
malariae, P. vivax, P.
ovale)
Positive for P.
knowlesi
(sequencing)
-
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Table 3 (Continued )
Ref. Case Microscopy RDTs Nested PCR Real-time PCR Other or not nearer
speciﬁed PCRs
Link et al.37 Netherlands, 2011 Negative (1st
examination)
Positive for P. malariae
(2nd examination)
Negative
(BinaxNOWe)
- Negative (real-time
PCR speciﬁc for P.
falciparum, P. vivax,
P. malariae, P. ovale)
Positive for P.
knowlesi (novel
real-time PCR
speciﬁc primers for
P. knowlesi SSU
rRNA)
-
Ehrhardt
et al.38
Germany, 2013 Positive for mixed P.
malariae and P. falciparum
infection
- - - Positive for P.
knowlesi (PCR and
sequencing)
Orth et al.39 Germany, 2013 Positive for P. malariae Negative for HRP2
(BinaxNOWe)
Positive for Pan-
Plasmodium
aldolase
(BinaxNOWe)
- - Positive for P.
knowlesi (PCR and
sequencing)
RDT, rapid diagnostic test; SSU, small subunit; LDH, lactate dehydrogenase; HRP2, P. falciparum-speciﬁc histidine-rich protein 2.
a Later positive for P. knowlesi examination of blood inoculated in rhesus monkeys and gibbons.
b BinaxNOW Malaria Test, Binax Inc., Maine, USA.
c The year of infection was unclear, so the year of publication has been used.
d Core Malaria Pan/Pv/Pf test, Core Diagnostics, Birmingham, UK.
e BinaxNOW Malaria Test, Iverness Medical, Sevres, France.
f Palutop Test, All Diag, Strasbourg, France.
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malaria-free zones by the WHO, travellers at potentially high risk
are those undertaking trips and trekking tours in forested or rural
areas in the deep hinterland. A lower risk of P. knowlesi infection is
reported from Thailand, but certain forested areas are considered
as malaria zones.60 The recent report of a French man acquiring a P.
knowlesi infection probably on a tourist beach on the Island of Ko
Payam, Thailand, indicates a risk in coastal areas as well,
particularly if they are situated near a forest.36Table 4
Infection associated with local travel in Southeast Asia
Ref. Year of
infection
Country of presentation Travel areas 
Jongwutiwes et al.15 2000 Bangkok, Thailand Prachuap, Khiri Khan 
Thailand
Ng et al.21
Jeslyn et al.20
2007
(5 cases)
2008
(1 case)
Singapore Lim Chu Kang, Singap
Cox-Singh et al.65 2010a Kota Kinabalu, Sabah,
Malaysia
Jungle of Borneo 
Lau et al.55 2009
2010
Malaysia
Malaysia
Raub, Pahang, Malays
Tanjung Malim, Perak
Lee et al.66 2008 Klang Valley,
Peninsular Malaysia
Klang Valley, Peninsu
Lee et al., 66 2007 Klang Valley,
Peninsular Malaysia
Bario Sarawak, Malay
Lee et al., 66 2008 Klang Valley,
Peninsular Malaysia
Pahang, Malaysia 
Lee et al., 66 2008 Klang Valley,
Peninsular Malaysia
Ampang, Malaysia 
Lee et al., 66 2008 Klang Valley,
Peninsular Malaysia
Labuan, Malaysia 
Lee et al., 66 2008 Klang Valley,
Peninsular Malaysia
Kuala Kubu, Selangor
Lee et al., 66 2008 Klang Valley,
Peninsular Malaysia
Klang Valley, Peninsu
a The year of infection was unclear, so the year of publication has been used.People travelling to known risk areas for P. knowlesi should use
malaria vector protection measures, such as insect repellents,61
mosquito nets, mosquito coils, aerosol sprays, and protective
clothes.60 Until more speciﬁc research contradicts this doctrine,
currently available chemoprophylaxis medication is effective
against P. knowlesi.54 A single case of possible resistance to
meﬂoquine has been reported in a Malaysian businessman, as
mentioned above.55 Patients presenting in non-endemic countries
with malaria-typical symptoms, such as fever, headache, malaise,Journey to
potential risky
areas (forest,
jungle, etc.)
Time to clinical
manifestations
after leaving the
place of potential
acquisition
Method of
diagnosis
Prophylaxis
Province, Forest 1 week PCR -
ore Forest 1–2 weeks PCR -
Jungle 10 days PCR -
ia
 Malaysia
Jungle
Jungle
2 weeks
15 days
PCR
PCR
-
-
lar Malaysia Jungle 2–3 weeks PCR -
sia - - PCR -
Forest 2–3 weeks PCR -
Jungle 3–4 weeks PCR -
Jungle 1 week PCR -
, Malaysia Riverside 1 week PCR -
lar Malaysia KKB, Malaysia - PCR -
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a history of travel to Malaysia, Myanmar, Thailand, Vietnam, or the
state of Palawan Philippines in the last 2 weeks, should be
investigated for a potential P. knowlesi infection.6 (Table 2)
The high rate of misdiagnosis of P. knowlesi infection as P.
falciparum or P. malariae by light microscopy in non-endemic
countries (Table 3) should lead to a new evaluation of diagnostic
techniques.29–39 PCR shows a high speciﬁcity and sensitivity, but
due to the complex process and high costs is not ideal.34,49 LAMP,Table 5
Drug treatment of Plasmodium knowlesi
Ref. Drug Count
cases
Singh et al.5 Chloroquine, primaquine 92 
Daneshvar et al.6 Chloroquine, primaquine 97 
Daneshvar et al.54 Chloroquine, primaquine 69 
Luchavez et al.23 Chloroquine, primaquine 2 
Chin et al.4 Chloroquine, primaquine 1 
Barber et al.8 Chloroquine, primaquine
(in children)
13 
Jongwutiwes et al.15 Chloroquine 1 
Ng et al.21 Chloroquine 1 
Berry et al.36 Chloroquine 1 
van Hellmond et al.33 Chloroquine 1 
Lee et al.66 Chloroquine - 
Singh et al.5
Barber et al.8
Quinine 5 
Daneshvar et al.6 Quinine 8 
Daneshvar et al.6 Quinine 2 
Cox-Singh et al.7 Quinine 1 
Bronner et al.29
Khim et al.24
Tanizaki et al.41
Meﬂoquine 3 
Lau et al.55 Meﬂoquine (resistance)
Later: quinine, doxycycline
Later: quinine, artemether,
lumefantrine
1 
Lau et al.55
Lee et al.66
Quinine
Doxycycline
4 
Kantele et al.30 Quinine, doxycycline
Later: primaquine
1 
Lee et al.66 Quinine, doxycycline
Later: chloroquine
1 
Barber et al.42 Artemether, lumefantrine 34 
Barber et al.42 Artesunate, meﬂoquine 119 
Barber et al.42 Artemether, lumefantrine, artesunate (intravenous) 75 
Orth et al.39 Artesunate (intravenous)
Later: artemether, lumefantrine
1 
Figtree et al.34 Atovaquone, proguanil 1 
Link et al.37
Ehrhardt et al.38
Atovaquone, proguanil 2 
Hoosen and Shaw35 Atovaquone, proguanil
Later: artemether, lumefantrine
1 
CDC31 Atovaquone, proguanil
Later: primaquine
1 
Singh et al.5 Chloroquine, primaquine, sulfadoxine, pyrimethamine 10 
Cox-Singh et al.7 Chloroquine, sulfadoxine, pyrimethamine 2 
Cox-Singh et al.7 Chloroquine, sulfadoxine, pyrimethamine, primaquine
Later: quinine
1 as described by Iseki et al. and Lau et al., could be a possible faster
and cheaper diagnostic tool, but further studies should be done to
evaluate the efﬁciency of this procedure.49,53 A recent publication
showed a low sensitivity of currently available RDTs in detecting P.
knowlesi. The development of more sensitive tests would also bring
the advantage of cheaper and faster handling under ambulatory
conditions.42 The latest research on protein structures as markers
for the detection of P. knowlesi, indicates promising progress in this
ﬁeld.62 Until ideal commercial diagnostic tests are developed, it is of Dose Outcome
n = 38:
Chloroquine 450–1350 mg (over 1–3 days); primaquine 15 or
7.5 mg (over 2–3 days/2 weeks)
n = 29:
Chloroquine 1500, 1200, or 1050 mg (over 3 days); primaquine 15
or 7.5 mg/day (for 3 days)
n = 14:
Chloroquine 1200 or 1500 mg (over 3 days); primaquine 15 or 7.5
mg/day (over 2–3 days)
n = 11:
Chloroquine 1500 mg (over 3 days); primaquine 15 or 7.5 mg (over
2–3 days/2 weeks)
Survived
Chloroquine 25 mg/kg (over 3 days); primaquine 15 mg/day (over
2 days)
Survived
Chloroquine 25 mg/kg (over 48 h); primaquine 15 mg Survived
Chloroquine 1500 mg (over 72 h); primaquine 45 mg (over 24 h) Survived
- Survived
- Survived
25 mg/kg (over 72 h) Survived
900 mg (over the ﬁrst 6 h); 600 mg/kg (over following 2 days) Survived
500 mg (1/day over 5 days) Survived
10 mg/kg; 5 mg/kg Survived
- Survived
- Survived
- Survived
Died
- Died
- Survived
Meﬂoquine 1500 mg
-
-
Survived
- Survived
- Survived
-
Chloroquine 150 mg
Survived
- Survived
- Survived
- Survived
Artesunate 2.4 mg/kg (1 day)
Artemether/lumefantrine
Survived
Atovaquone 250 mg; proguanil 100 mg (4/day over 3 days) Survived
Atovaquone 1000 mg/day; proguanil 400 mg/day (over 3 day) Survived
- Survived
- Survived
Chloroquine + primaquine; sulfadoxine 1000 mg (single dose);
pyrimethamine 50 mg (single dose)
Survived
- Died
- Died
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efﬁcient way. This is especially important for infections with
morphological structures similar to P. malariae on light microscopy
in those with a history of travel to Malaysia and a low platelet
count, who should be suspected of having a possible P. knowlesi
infection.2,8,9 (Table 4)
Immediate hospitalization and initiation of treatment are
imperative due to the 24-h replication cycle and the potential
severity of the ﬁfth human malaria.6,7 Indicators for a potential
severe course have been described by Willmann et al.43 and Barber
et al.,42 as mentioned above. Patients showing signs of a severe
knowlesi infection should be treated according to the guidelines
for severe P. falciparum infections, with parenteral medica-
tion.42,60,63
Several treatment regimens are reported to be effective against
P. knowlesi, including the chloroquine/primaquine combination.54
Due to the fact that no hypnozoites have ever been described in P.
knowlesi infection, primaquine is probably not required as a
treatment except in cases of mixed infection with P. vivax. Further
studies are needed to evaluate the optimal prevention and
treatment of P. knowlesi, especially in view of increasing resistance
to the concomitantly occurring P. falciparum in Southeast Asia.
Recent studies have shown the efﬁcacy of ACT, such as artemether–
lumefantrine and artesunate–meﬂoquine, in non-severe P. know-
lesi infections, as well as intravenous artesunate in severe
cases.42,64 These treatment regimens appear promising, particu-
larly in view of the often multi-resistant, co-endemic P. falciparum
and P. vivax infections. In addition, ACTs have a signiﬁcantly faster
parasite clearance compared to chloroquine.64
4. Conclusions
P. knowlesi appears to be a widespread human malaria parasite
in Malaysian Borneo65,66. This paper illustrates that the ﬁfth
human parasite is not only a threat to residents, but also to
occupational and holiday travellers. Despite the increasing
prevalence in Malaysia, infection rates in travellers remain low,
but the extent of misdiagnosed cases remains uncertain. A special
risk group are travellers to forested and rural areas. At lower, but
still underestimated risk of P. knowlesi infection, are travellers to
Thailand, the Philippines, Indonesia, Myanmar, and Vietnam, and
probably also Cambodia. Clinicians who provide pre-travel advice
or who consult ill returning travellers should be aware of the risk.
Adequate preventive measures, such as mosquito nets, insect
repellents, and the wearing of protective clothing, should be
recommended together with appropriate antimalarials. In travel-
lers who present with malaria-typical symptoms and a recent
history of travel to Malaysia or neighbouring areas in Southeast
Asia, a probable P. knowlesi infection has to be taken into
consideration. If blood smears are positive for P. malariae, a P.
knowlesi infection has to be strongly suspected, especially if
accompanied by low thrombocyte counts. Due to the fast
reproduction cycle and a potentially severe progression, patients
who are suspected of having a P. knowlesi infection should be
hospitalized and treated immediately.
Conﬂict of interest: The authors declare that they have no conﬂict
of interest with this work.
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